Prothena is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of devastating neurological disorders.
We are advancing a pipeline of therapeutic candidates for a number of indications and novel targets including Parkinson’s disease and other related synucleinopathies (prasinezumab, PRX002/RG7935) and ATTR amyloidosis (PRX0...
Prothena is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of devastating neurological disorders.
We are advancing a pipeline of therapeutic candidates for a number of indications and novel targets including Parkinson’s disease and other related synucleinopathies (prasinezumab, PRX002/RG7935) and ATTR amyloidosis (PRX004), as well as tau, and TDP-43 where our scientific understanding of disease pathology can be leveraged.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.